COVID-19 Returns with a New Face: Rapid Spread of JN.1 Variant Alarms Experts

COVID-19 Returns with a New Face: Rapid Spread of JN.1 Variant Alarms Experts
COVID cases are rising sharply across Asia, including India. Experts blame the JN.1 variant, a mutated form of Omicron, for the sudden spike.

COVID-19 Makes a Comeback: JN.1 Variant Fuels New Wave of Infections. The COVID-19 pandemic, which once seemed to have receded, is now showing signs of a dangerous return in various Asian countries. A sudden increase in cases has been observed in India, Singapore, Hong Kong, China, and Thailand. The reason? A new and highly transmissible variant named JN.1, a subvariant of Omicron.

According to health experts, the JN.1 variant originated from the BA.2.86 (Pirola) strain and was first detected in late 2023. Since then, it has spread across the United States, UK, Singapore, India, and Hong Kong. Now, it’s back and spreading at an alarming pace.

Read More :  Cyclone ‘Dana’ Gains Strength, Storm Speed Increase Upto 125 KM/h

Why Is JN.1 a Concern? The JN.1 variant shows significant mutations in its spike protein, allowing it to bind more easily to human cells. This makes it highly transmissible and more resistant to existing immunity. Even people who have previously been infected or vaccinated may not be fully protected.

COVID-19 Returns with a New Face: Rapid Spread of JN.1 Variant Alarms Experts

COVID-19 Returns with a New Face: Rapid Spread of JN.1 Variant Alarms Experts
COVID-19 Returns with a New Face: Rapid Spread of JN.1 Variant Alarms Experts

The World Health Organization (WHO) has classified JN.1 as a “Variant of Interest” (VOI), meaning it is under close observation and study. While it hasn’t yet proven to be more deadly than Omicron, its ability to spread rapidly is causing global concern.

Read More :  Delhi Winter 2024 Set to be Colder Due to Strengthening La Niña, Warns IMD

Common Symptoms of JN.1: Sore throat, Runny nose, Fatigue, Cough, Fever and Headache

In Singapore, two more subvariants — LF.7 and NB.1.8 — are also contributing to the current wave. Both are offshoots of JN.1 and are associated with additional symptoms like: Conjunctivitis, Diarrhea, Loss of taste and smell.

Vaccine Effectiveness Against JN.1: The mRNA vaccines, including Pfizer-BioNTech and Moderna, appear to provide partial protection against JN.1. While they may not completely prevent infection, they significantly reduce the risk of hospitalization, severe illness, or death. Those who have taken booster doses in 2023–2024 are at a lower risk of complications.

Who Should Be More Cautious? People with comorbidities such as diabetes, cancer, heart disease, or weakened immune systems are particularly vulnerable. Health experts urge such individuals to wear masks, avoid crowded places, and keep vaccinations up to date.

Read More :  Tragic Death of 26-Year-Old EY Employee Sparks Outcry Over Toxic Workplaces in India

Be the first to comment

Leave a Reply

Your email address will not be published.


*